Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoma: early-phase trial registry
88 of 330 indexed Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #21 of 28,707 conditions by registered trial count.
330 US clinical trials · 88 currently recruiting · #21 of 28,707 conditions by registered trial count
Lymphoma: 330 US clinical trials tracked, 88 recruiting.
Lymphoma is the subject of 330 registered US clinical trials on ClinicalTrials.gov, 88 of them currently open to new participants. 25 are in Phase 3-4 (later-stage) and 229 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 34 of these trials.
Enrollment posture brief
Registry condition lymphoma
OPEN 88 | RECR 27% | LATE 25 | EARLY 229 | RANK #21 | SPON 34
Volume-matched condition peers
Nearest open-share peer: Age-related Macular Degeneration (27% recruiting · 75 trials)
Lymphoma lists 88 open slots (27% of 330 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphoma is recruiting below its size-band peers.
88 of 330 indexed trials (26.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lymphoma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 34 of 330 trials (10.3%). 116 distinct sponsors appear on at least one study for this condition label.
-
Most Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 300 trials that report a genuine target (sentinel values excluded). 213 of those (71%) plan for fewer than 100 participants.
-
Lymphoma research is mostly interventional.
299 interventional and 31 observational studies make up this index (90.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
330 total, page 5 of 7
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
NCT00816595
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Alliance for Clinical Trials in Oncology
NCT01027000
Safety and Efficacy of Campath in Nonmyeloablative Transplantation
M.D. Anderson Cancer Center
NCT00038844
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
M.D. Anderson Cancer Center
NCT01983969
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
NCT00002565
Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies
Wake Forest University Health Sciences
NCT02305979
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Incyte Corporation
NCT02998476
The Effects of Anthracycline-based Chemotherapy on Peripheral Vascular Function
Carl Ade, M.S., Ph.D.
NCT03062878
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
M.D. Anderson Cancer Center
NCT00857389
A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers
University of Michigan Rogel Cancer Center
NCT02409121
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
Jennifer Amengual
NCT01947140
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
Merck Sharp & Dohme
NCT00086125
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
Millennium Pharmaceuticals
NCT01844583
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT00410657
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
NCT01190449
Cladribine in Patients With Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
NCT00002879
Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00002553
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
Memorial Sloan Kettering Cancer Center
NCT00546377
Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Jonsson Comprehensive Cancer Center
NCT00138164
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
David Rizzieri, MD
NCT00578942
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
Alliance for Clinical Trials in Oncology
NCT00098774
Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy
Pack Health
NCT05064787
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
NCT00003398
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Northwestern University
NCT00058292
Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Case Comprehensive Cancer Center
NCT00265889
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
Masonic Cancer Center, University of Minnesota
NCT00602693
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
Duke University
NCT00606437
Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Alliance for Clinical Trials in Oncology
NCT00003849
Rituximab in Treating Patients With Hodgkin's Lymphoma
Ranjana Advani
NCT00003820
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT00534118
Exercise Program for Adolescents and Young Adults With Cancer
M.D. Anderson Cancer Center
NCT00502749
Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
NCT00098566
Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders
Memorial Sloan Kettering Cancer Center
NCT00052572
Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
Roswell Park Cancer Institute
NCT00002578
506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
National Cancer Institute (NCI)
NCT00003545
Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma
Arno Therapeutics
NCT00978523
VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
Vion Pharmaceuticals
NCT00304005
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
AIDS Malignancy Consortium
NCT00392834
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Case Comprehensive Cancer Center
NCT00054327
S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
NCT00109928
Campath-1H + FK506 and Methylprednisolone for GVHD
Case Comprehensive Cancer Center
NCT00109993
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Northwestern University
NCT00466921
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
Triphase Research and Development III
NCT03682796
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
City of Hope Medical Center
NCT00589563
Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma
University of Nebraska
NCT00572013
Ixazomib Rollover Study
Takeda
NCT02924272
Immune Reconstitution in Oncology Patients Following Autologous Stem Cell Transplant
St. Jude Children's Research Hospital
NCT01540175
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
NCT00516217
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
National Cancer Institute (NCI)
NCT00013533
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Memorial Sloan Kettering Cancer Center
NCT00667615
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 119 |
| Phase 2 | 110 |
| Phase 3 | 22 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphoma page
330 registered trials, 88 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 88 Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Lymphoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoma condition card totals 330 registered trials; most-linked intervention cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.